Ionis Brings Treatment for Gastrointestinal Immune Disorders to Clinical-trial Stage

Ionis Brings Treatment for Gastrointestinal Immune Disorders to Clinical-trial Stage
Janssen Biotech plans a Phase 1 clinical trial of a therapy that its partner Ionis Pharmaceuticals developed as a treatment for gastrointestinal immune disorders. Under their collaboration agreement, Ionis received $5 million for bringing the therapy, IONIS-JBI 1-2.5 Rx, to the clinical-trial stage. Janssen is responsible for obtaining regulatory approval of the treatment worldwide, and commercializing it. Ionis stands to gain

Knowledge is power when living with IBD.

Get access to the web’s leading IBD news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *